Advanced search    

Search: authors:"Joseph M Herman"

10 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Pancreatic adenocarcinoma: current treatment approaches and controversies

Joseph M. Herman 0 ) Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University , Baltimore, MD, USA - In 2013, there will be an estimated 43,920 new cases and 37

The Promise of Modern Radiotherapy in Resected Pancreatic Adenocarcinoma: A Response to Bekaii-Saab et al.

Determining the optimal adjuvant management strategy for patients with resected pancreatic adenocarcinoma remains a controversial topic. In particular, defining the role for radiation continues to generate significant debate. As such, we welcome sustained investigation into whether radiation can improve oncologic outcomes after resection of pancreatic cancer. We therefore...

Phosphorus-32, a Clinically Available Drug, Inhibits Cancer Growth by Inducing DNA Double-Strand Breakage

Radioisotopes that emit electrons (beta particles), such as radioiodine, can effectively kill target cells, including cancer cells. Aqueous 32P[PO4] is a pure beta-emitter that has been used for several decades to treat non-malignant human myeloproliferative diseases. 32P[PO4] was directly compared to a more powerful pure beta-emitter, the clinically important 90Y isotope. In...

The role of 18F-fluorodeoxyglucose positron emission tomography in the management of patients with pancreatic adenocarcinoma

Lujaien A Kadhim Avani S Dholakia Joseph M Herman Richard L Wahl Muhammad A Chaudhry 0 ) Division of Nuclear Medicine, Department of Radiology, Johns Hopkins University School of Medicine , 601 N

Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor–vessel relationships

Objective Neoadjuvant therapy increases rates of margin-negative resection of borderline resectable pancreatic ductal adenocarcinoma (BL-PDAC). Criteria for BL-PDAC resection following neoadjuvant chemotherapy and radiation therapy (NCRT) have not been clearly defined. Methods Fifty consecutive patients with BL-PDAC who received NCRT from 2007 to 2012 were identified. Computed...

Concurrent versus Sequential Sorafenib Therapy in Combination with Radiation for Hepatocellular Carcinoma

Sorafenib (SOR) is the only systemic agent known to improve survival for hepatocellular carcinoma (HCC). However, SOR prolongs survival by less than 3 months and does not alter symptomatic progression. To improve outcomes, several phase I-II trials are currently examining SOR with radiation (RT) for HCC utilizing heterogeneous concurrent and sequential treatment regimens. Our...

ACR Appropriateness Criteria®  Resectable Rectal Cancer

Radiation Oncology ACR Appropriateness Criteria William E Jones III 8 Charles R Thomas Jr 0 Joseph M Herman 7 May Abdel-Wahab 13 Nilofer Azad 12 William Blackstock 11 Prajnan Das 10 Karyn A Goodman

Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital - Mayo Clinic collaborative study

Richard D Schulick 5 6 Christopher L Wolfgang 5 6 John L Cameron 5 6 Joseph M Herman 0 5 0 Department of Radiation Oncology, Johns Hopkins University School of Medicine , Baltimore, MD , USA 1 Department of

Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study

Background Survival for pancreatic ductal adenocarcinoma is low, the role of adjuvant therapy remains controversial, and recent data suggest adjuvant chemoradiation (CRT) may decrease survival compared with surgery alone. Our goal was to examine efficacy of adjuvant CRT in resected pancreatic adenocarcinoma compared with surgery alone. Materials and Methods Patients with...